CYP2C19 and myopathy: Moreover, pharmacogenomic insights exemplified by CYP2C19 genotyping to guide clopidogreland SLCO1B1 testing to mitigate statin-induced myopathy have demonstrated the capacity to reduce adverse events and optimize drug efficacyin routine practice [4].